Data sources SEC FORM 4 3h ago
HOUSE PTR 3h ago
SEC 13F 3h ago
ROBINHOOD CHAIN 3h ago
Public company DAWN Day One Biopharmaceuticals, Inc.CIK 0001845337
Disclosed transactions 60
Buys / sells 0 / 0
Max Insider Score 9
Connections 10 with evidence
DAWN · disclosed activity on price
Score Actor Security Side Value Executed Disclosed Lag Source Evidence 9 DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 15.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9
VM Vasconcelles Michael Head of Research and Dev.
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
Apr 23, 2026traded Apr 23, 2026
9 GW Grossman William Director
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 22.5K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 22.5K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 VM Vasconcelles Michael Head of Research and Dev.
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 346.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 VM Vasconcelles Michael Head of Research and Dev.
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 171.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 GW Grossman William Director
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 66.7K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 BJ Bender Jeremy Director, CHIEF EXECUTIVE OFFICER
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 14.3K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 32.3K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 BJ Bender Jeremy Director, CHIEF EXECUTIVE OFFICER
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 286.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 63.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DA Dubow Adam Gen Counsel & Secretary
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 25.8K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DA Dubow Adam Gen Counsel & Secretary
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 5,250 sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DA Dubow Adam Gen Counsel & Secretary
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 105.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DA Dubow Adam Gen Counsel & Secretary
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 40.6K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 VM Vasconcelles Michael Head of Research and Dev.
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 106.9K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DA Dubow Adam Gen Counsel & Secretary
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 90.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DA Dubow Adam Gen Counsel & Secretary
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 90.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 BJ Bender Jeremy Director, CHIEF EXECUTIVE OFFICER
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 286.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 66.7K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 BJ Bender Jeremy Director, CHIEF EXECUTIVE OFFICER
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 147.7K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 BJ Bender Jeremy Director, CHIEF EXECUTIVE OFFICER
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 244.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 ML Merendino Lauren Chief Commercial Officer
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 90.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 ML Merendino Lauren Chief Commercial Officer
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 330.2K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 72.3K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 ML Merendino Lauren Chief Commercial Officer
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 69.4K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 15.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 22.5K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DA Dubow Adam Gen Counsel & Secretary
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 309.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DA Dubow Adam Gen Counsel & Secretary
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 90.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 BJ Bender Jeremy Director, CHIEF EXECUTIVE OFFICER
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 300.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DA Dubow Adam Gen Counsel & Secretary
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 8,889 sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 BJ Bender Jeremy Director, CHIEF EXECUTIVE OFFICER
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 20.2K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 VM Vasconcelles Michael Head of Research and Dev.
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 4,397 sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 BJ Bender Jeremy Director, CHIEF EXECUTIVE OFFICER
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 397.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 BJ Bender Jeremy Director, CHIEF EXECUTIVE OFFICER
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 808.3K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 BJ Bender Jeremy Director, CHIEF EXECUTIVE OFFICER
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 355.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 ML Merendino Lauren Chief Commercial Officer
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 19.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 YN York Charles N II COO and CFO
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 162.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 GW Grossman William Director
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 32.3K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DA Dubow Adam Gen Counsel & Secretary
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 65.6K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 GW Grossman William Director
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 15.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 BJ Bender Jeremy Director, CHIEF EXECUTIVE OFFICER
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 204.6K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 BJ Bender Jeremy Director, CHIEF EXECUTIVE OFFICER
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 300.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 BJ Bender Jeremy Director, CHIEF EXECUTIVE OFFICER
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 18.2K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 BJ Bender Jeremy Director, CHIEF EXECUTIVE OFFICER
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 1.46M sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 BJ Bender Jeremy Director, CHIEF EXECUTIVE OFFICER
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 128.6K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 BJ Bender Jeremy Director, CHIEF EXECUTIVE OFFICER
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 81.8K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 BJ Bender Jeremy Director, CHIEF EXECUTIVE OFFICER
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 222.2K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 ML Merendino Lauren Chief Commercial Officer
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 60.2K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 ML Merendino Lauren Chief Commercial Officer
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 110.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 ML Merendino Lauren Chief Commercial Officer
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 90.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 ML Merendino Lauren Chief Commercial Officer
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 25.8K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 ML Merendino Lauren Chief Commercial Officer
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 40.6K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 28.7K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 1,181 sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 37.5K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 32.3K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 DA Dubow Adam Gen Counsel & Secretary
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 72.7K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
9 YN York Charles N II COO and CFO
DAWN Day One Biopharmaceuticals, Inc. Disposition to issuer
D — 312.0K sh
Apr 23, 2026 Apr 23, 2026traded Apr 23, 2026
+0d SEC FORM 4 Evidence
Evidence Close
Director, CHIEF EXECUTIVE OFFICER · Nov 7, 2025
Source error Price history for DAWN is unavailable.
An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.